Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Celgene Expands Pact With Forma
by Ann M. Thayer
April 7, 2014
| A version of this story appeared in
Volume 92, Issue 14
Celgene has set up a second collaboration with Forma Therapeutics in a range of therapeutic areas. Just a year ago, the two companies signed a deal worth more than $200 million around drugs that regulate protein homeostasis. Under a new three-and-a-half-year agreement, Celgene will pay Forma $225 million up front. Celgene also has the option to establish two more two-year agreements for another $375 million. If the latter collaboration happens, Celgene will have an exclusive option to acquire Forma, whose drug discovery technology comes from Broad Institute researchers.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter